Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

For head and neck cancers do you ever reduce PTV coverage in the post-op setting to meet an OAR constraint?

1
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Michigan

There is no real clinical constraint regarding parotid glands doses. The threshold of 26 Gy mean dose was based on forward-planning IMRT in the early 1990s, which could spare the contralateral but not the ipsilateral glands. Once inverse planning was available and partial sparing of the ipsilateral ...

Would you omit a boost in a patient with an indication if a very large (>200cc) post-op seroma obscures the actual tumor bed?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Generally for these patients with seroma > 100 cc, prefer aspiration and settling of seroma before starting RT. Also in general, we tend to rescan for boost most of the time as favor lateral decubitus position and also account for change in size of seroma. Kannan et al., PMID 23006598

Would you consider treating an adult patient with severe claustrophobia with daily anesthesia for 35 fractions if the goal is larynx preservation?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Medical University of South Carolina (Charleston)

This is an anecdotal case. I did this once for a patient. T3N0 SGL. Anesthesia wanted a trach to secure the patient's airway (was placed prior to starting treatment). General anesthesia for 35 treatments. Trach was removed soon after completing treatment. The patient is now 8 years post-treatment, l...

Would you offer definitive XRT for muscle invasive bladder cancer arising within a bladder diverticulum?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Stony Brook University School of Medicine

A diverticulum is a common location for bladder cancer to arise. I am not aware of any association between RT diverticula and increased risk of bladder perforation. I have personally never had an issue treating diverticula to full dose (either 64 Gy in 2 Gy fractions or 55 Gy in 20 fractions) in ter...

Will the recent publication of the KROG 08-06 trial change your practice in node positive breast cancer patients?

6
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Northwestern University

I would encourage listening to Dr. @Dr. First Last's ASTRO discussion of this trial.KROG 08-06 was powered to detect a 10% DFS advantage for inclusion of the IM chain. Meanwhile, RNI trials have demonstrated a 3-5% advantage in DFS for RNI such that even if irradiation of the IM chain were responsib...

How would you approach unresectable synovial sarcoma of the heart ?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · The Ohio State University - James Cancer Hospital and Solove Research Institute

The specific situation described is rare and I'm not aware of any data addressing it directly, but there are general principles for cardiac sarcomas that can be helpful.For cardiac sarcomas, subsite matters for prognosis and treatment. Left-sided more prone to non-lung visceral mets. (In resectable ...

Do you recommend ADT for all patients who are unfavorable intermediate risk prostate cancer?

4
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Rutgers Cancer Institute of New Jersey

I recommend ADT for unfavorable intermediate risk patients who are not treated with a brachy boost. ADT is probably unnecessary for those treated with brachy boost. Of course, I also take into account the patient's concerns and preferences regarding sexuality, cardiac risk, and desire for maximal tr...

In what situations would you consider focal irradiation for nodular leptomeningeal disease?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Columbia University Irving Medical Center

So in general, for patients with LMD, I would recommend WBRT - if RT were indicated. A recent paper in the red journal (Turner et al., PMID 31605786) separated "classical LMD" versus "nodular LMD" and provided a training module to improve interrater reliability. In my practice, even patients who pre...

Do you treat the normal pancreas as an organ at risk when delivering abdominal radiation therapy?

5 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan-Kettering Cancer Center

This is a great question. We do not do that because we have not seen any convincing evidence of exocrine or endocrine insufficiency caused by radiation at any dose. In fact, from surgical patients, we know that only a small volume of residual pancreas is needed to prevent insulin dependence. The pan...

How does the presence of CABG affect your radiotherapy approach for definitive management of locally advanced NSCLC with mediastinal involvement?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Cedars-Sinai Medical Center

This is a great question. The short answer is we don’t exactly know – but the longer answer would be that while CABG graft dosimetry hasn’t been explicitly defined, we can make a few reasonable extrapolations and assumptions. We know that patients with +CAD are at very high risk of cardiac events, a...